Persistent HIV-1 replication does not explain low levels of T-cell interferon-γ mRNA and elevated serum NO2-/NO 3- in patients with stable CD4 T-cell responses to HAART

Clinical and Experimental Immunology

Volumn 138, Issue 1, 2004, Pages 110-115

  Lee, Silvia ^a,b   Almeida, C A ^a,b   French, M A H ^a,b   Price, P ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cytokine; HAART; HIV; RT PCR

Indexed keywords

CD30 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CRTH2; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 5; MESSENGER RNA; NITRATE; NITRITE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS CULTURE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; ANTIGENS, CD30; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; NITROGEN DIOXIDE; NITROGEN OXIDES; RECEPTORS, CCR5; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RNA, MESSENGER; RNA, VIRAL; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 4644319215     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02589.x     Document Type: Article

References (29)

1. Mathez D, Bagnearelli P, Gorin I et al. Reduction in viral load and increases in T lymphocyte numbers in treatment-naïve patients with advanced HIV-1 infection treated with ritonavir, zidovudine, zalcitabine triple therapy. Antiviral Ther 1997; 2:175-3.
2. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-6.
3. Mezzaroma I, Carlesimo M, Pinter E et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999; 13:1187-93.
4. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
5. Keane N, Price P, Stone SF, John M, Murray RJ, French MA. Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2000; 16:1991-6.
6. Sieg SF, Mitchem JB, Bazdar DA, Lederman MM. Close link between CD4+ and CD8+ T cell proliferation defects in patients with human immunodeficiency virus disease and relationship to extended periods of CD4+ lymphopenia. J Infect Dis 2002; 185:1401-8.
7. Keane NM, Price P, Lee S et al. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV patients responding to HAART. HIV Med 2004; (in press).
8. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002; 76:9011-23.
9. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15:575-81.
10. Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch FM. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 1999; 15:1499-508.
11. Taoufik Y, Peguillet I, de Goer MG et al. Effect of highly active antiretroviral therapy on expression of interleukin-10 and interleukin-12 in HIV-infected patients. J AIDS 2001; 26:303-4.
12. Kaufmann D, Pantaleo G, Sundre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study Lancet 1998; 351:723-4.
13. Piketty C, Castiel P, Belec L et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-50.
14. Renaud M, Katlama C, Mallet A et al. Determinants of paradoxical CD4 cell regeneration after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-76.
15. D'Ettorre G, Forcina G, Andreotti M et al. Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production. AIDS 2002; 16:1877-85.
16. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4+ T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999; 94:1021-7.
17. Deeks S, Hoh R, Grant RM et al. CD4+ T cell kinetics and activation in human immunodeficiency-virus infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-23.
18. Stoddart CA, Liegler TJ, Mammano F et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001; 7:712-8.
19. Cosmi L, Annunziato F, Iwasaki M, Maggi RME, Nagata K, Romagnani S. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 2000; 30:2972-9.
20. Van't Hof RJ, Ralston RH. Nitric oxide and bone. Immunology 2001; 103:255-61.
21. Del Prete G, De Carli M, Almerigogna F et al. Preferential expression of CD30 by human CD4 T cells producing Th2-type cytokines. FASEB J 1995; 9:81-6.
22. Yamamoto S, Hamasaki Y, Ishii E, Ichimaru T, Miyazaki S. Unbalanced production of interleukin-5 and interleukin-2 in children with atopic dermatitis. Ann Allergy Asthma Immunol 1997; 78:517-23.
23. Naif HM, Li S, Alali M et al. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998; 72:830-6.
24. Lee S, MacQuillan GC, Keane NM et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Immunol Cell Biol 2002; 80:391-7.
25. Martinon F, Michelet C, Peguillet I et al. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. AIDS 1999; 13:185-94.
26. Weiss L, Burgard M, Cahen YD et al. Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy. HIV Med 2002; 3:12-20.
27. Keane NM, Price P, Lee S, Stone SF, French MA. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001; 26:111-6.
28. Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996; 157:3229-34.
29. Manetti R, Annunziato F, Biagiotti R et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+30+ T cell clones in human immunodeficiency virus infection. J Exp Med 1994; 180:2407-11.